Clinical News

UEG is calling on all EU countries to evaluate advanced CRC screening techniques to help increase survival rates

Tuesday, 17 March 2015 10:14

The Colorectal Cancer Awareness month kicks off UEG's latest campaign "Screening Saves Lives (CRC) 2015". Colorectal cancer accounts for about half of all gastrointestinal malignancies in Europe and the annual incidence is predicted to rise by 12% by 2020. UEG is calling on everyone over 50 to 'Step Up, Take the Test'. Read full press release and follow this campaign on Twitter #ScreeningSavesLives.

Nice Quality Standards for IBD

Friday, 27 February 2015 10:42

Professor Chris Probert, Chair BSG IBD Section Committee

"The BSG welcomes the release of Quality Standards for IBD by NICE. The four statements are necessarily succinct and members should read the more detailed version on the NICE website. This document sets a standard that should be recognised by CCGs and Trusts and should enable us to raise the quality of our services. These standards should form the basis of the forthcoming IBD Accreditation, along with the IBD Audit and Registry."

Changes in HCV therapy - approval of Sofosbuvir

Friday, 30 January 2015 13:55

Dr Stephen Ryder, BSG Vice-President Hepatology & Dr Andrew Austin, Chair BSG Liver Section

There are two major changes in HCV therapy which now have NICE and/or NHSE approval for use. The first is that commissioning guidance for the use of Simiprevir is published (http://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-a/a02/). This allows G1 patients without Q80K to access triple therapy now using Simiprevir instead of Boceprevir or Telaprevir.

The second and probably more significant development is the approval of Sofosbuvir. The approval can be summarised as below:

 

Sofosbuvir in combination with pegylated interferon + ribavirin (Peg-IFN+RBV)

HCV genotype Adult patient population
Genotype 1 Treatment-naïvea
  Treatment-experienceda
Genotype 3 Treatment-naïve with cirrhosisa
  Treatment-experienceda
Genotype 4, 5, or 6 Treatment-naïve & experienced with cirrhosisa

 

Sofosbuvir in combination with RBV

HCV genotype Adult patient population
Genotype 2 Treatment-naïveb
Treatment-experienceda
Genotype 3 Treatment-naïve with cirrhosisb
Treatment-experienced with cirrhosisb

The NHSE approval is for cirrhotic patients to access treatment in April with non-cirrhotic patients from July.

There is a meeting at Barts on 3rd March 2015 (advertised by BVHG) to establish clinical guidelines as to who to treat with what when. It is highly likely that by July other agents approvals will make the interferon component of the regimen outdated. NHSE will establish a process by which the drugs will be distributed shortly but it would seem prudent for centres to enter local negotiations now in order all are ready to prescribe when we are given the approvals. It is pretty certain that similar data gathering will be required as for EAP.

Lancet liver recommendations must be implemented to address crisis

Tuesday, 25 November 2014 00:00

The British Society of Gastroenterology (BSG) has today urged for the Lancet Commission UK Liver Disease Publication recommendations to be pursued "without delay" to "address the UK liver disease crisis".

Liver Disease mortality rates have increased by 400% since 1970 and is the third most common form of premature death in the UK.

The most common form of liver disease is alcohol-related, followed by fatty liver disease caused by obesity. The steep rise in both alcohol consumption and obesity in recent decades has led to increases in both conditions.

Incidences of chronic viral hepatitis are also on the rise, with annual deaths from hepatitis C having quadrupled since 1996, and significant increases in hepatitis B infection.

The Lancet report calls for wide-reaching, joined-up action including:

  1. Better detection of early disease in primary care
  2. Improved support services in community settings
  3. The establishment of Liver Units in District General Hospitals
  4. A national review of liver transplantation services
  5. Strengthening of continuity of care for children with liver disease surviving into adult life
  6. A range of population-level measures such as a minimum unit price for alcohol
  7. Promotion of healthier lifestyles with clearer government messaging and new regulations on the food industry
  8. Eradication of chronic HBV and HCV infection from the country by 2020
  9. Greater provision of medical training in hepatology
  10. A national campaign led by NHS England to increase awareness of liver disease in the general population

Page 3 of 4